3 Reasons to Buy Novavax Stock, and 1 Reason to Sell
Novavax (NASDAQ: NVAX) is nearing the finish line of the coronavirus vaccine race. The clinical-stage biotech company expects to report interim data from a phase 3 trial in the early part of this quarter. All eyes will be on those results, because they'll support the company's request for emergency authorization in countries around the world.
Novavax is at a critical juncture. Overall, I'm positive about Novavax's prospects -- so positive that I can think of three reasons to buy shares. But nothing is perfect, right? And that's why I'm also able to find one reason to sell the stock. Consider these points before making either move.
Image source: Getty Images.
Source Fool.com
